| abstract |
The present invention provides a novel heteroaromatic compound as an Autotaxin (ATX) inhibitor, a pharmaceutical composition comprising the compound, and a use thereof in a treatment of a disease with a pathological feature of Autotaxin (ATX) overexpression in a mammal, wherein the compound is according to formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, nitrogen oxide, metabolite, prodrug, or mixture thereof; wherein each of R<sup>1</sup>, Ar<sup>1</sup>, Ar<sup>2</sup>, Ar<sup>3</sup>, W, Y, Z, and Cy is defined in the present invention. |